Proposal to widen hospital funding restrictions for rituximab

• Cold haemagglutinin disease;
• Warm autoimmune haemolytic anaemia;
• Immune thrombocytopenic purpura;
• Thrombotic thrombocytopenic purpura;
• Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis;
• Systemic lupus erythematosus;
• Antibody-mediated renal transplant rejection; and
• ABO-incompatible renal transplant.

We do not have a proposed implementation date because it would be dependent on the consultation responses received. We may have to seek further clinical advice following consultation. We will notify all relevant parties when a decision is made on any aspect of this proposal.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Monday, 30 September 2013 to:

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.